Advertisement
Screener

EQUILLIUM, INC. (EQ) Graph

EQ Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development (m); Operating expenses $5.16M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development (m); Operating expenses $5.61M; Income tax (m).
  • 2025-12-31: Revenue (m); Research and development (m); Operating expenses $3.96M*; Income tax $0.00*.
  • 2025-09-30: Revenue (m); Research and development (m); Operating expenses $4.58M; Income tax $0.00.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)(m)$5.16M(m)-$4.69M
2026-03-31(m)(m)$5.61M(m)-$5.31M
2025-12-31(m)(m)$3.96M*$0.00*-$3.77M*
2025-09-30(m)(m)$4.58M$0.00-$4.23M
2025-06-30(m)(m)$6.23M$0.00-$5.74M
2025-03-31(m)(m)$8.87M$0.00-$8.65M
2024-09-30$12.16M(m)$12.84M$0.00-$7.00K
2024-06-30$13.85M(m)$13.95M$0.00$468.00K
2024-03-31$10.69M(m)$13.48M$0.00-$2.73M
2023-09-30$8.87M(m)$12.49M$496.00K-$3.71M
2023-06-30$9.12M(m)$12.71M$8.00K-$3.34M
2023-03-31$8.88M(m)$12.99M$60.00K-$3.94M
2022-09-30(m)(m)$13.24M$0.00-$13.65M
2022-06-30(m)(m)$13.55M$0.00-$14.13M
2022-03-31(m)(m)$37.33M$0.00-$37.42M
2021-09-30(m)$6.96M$9.86M(m)-$10.28M
2021-06-30(m)$5.99M$8.84M(m)-$9.16M
2021-03-31(m)$5.88M$8.70M(m)-$8.99M
2020-12-31(m)(m)$8.97M(m)-$8.92M
2020-09-30(m)$4.22M$6.52M(m)-$6.60M
2020-06-30(m)$3.89M$6.61M(m)-$6.46M
2020-03-31(m)$4.71M$7.45M(m)-$7.84M
2019-12-31(m)(m)$7.62M(m)-$7.57M
2019-09-30(m)$4.18M$6.32M(m)-$6.01M
2019-06-30(m)$4.25M$6.44M(m)-$6.07M
2019-03-31(m)$3.76M$6.35M(m)-$5.95M
2018-12-31(m)(m)$4.23M(m)-$4.99M
2018-09-30(m)$1.22M$2.23M(m)-$4.92M
2018-06-30(m)$540.00K$1.13M(m)-$1.76M
2018-03-31(m)$663.00K$1.04M(m)-$1.58M
2017-12-31(m)(m)-$639.80K(m)-$1.11M
2017-09-30(m)$49.95K-$83.71K(m)-$141.03K
2017-06-30(m)(m)-$921.34K(m)-$947.30K

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)(m)$10.77M(m)-$10.00M
2025-06-30(m)(m)$15.10M$0.00-$14.39M
2024-06-30$24.54M(m)$27.43M$0.00-$2.27M
2023-06-30$18.00M(m)$25.70M$68.00K-$7.28M
2022-06-30(m)(m)$50.88M$0.00-$51.55M
2021-06-30(m)$11.87M$17.54M(m)-$18.15M
2020-06-30(m)$8.60M$14.06M(m)-$14.30M
2019-06-30(m)$8.01M$12.79M(m)-$12.02M
2018-06-30(m)$1.20M$2.16M(m)-$3.34M

Revenue and expense 7 month

Period endResearch and developmentOperating expensesNet income
2017-09-30$851.31K$1.07M-$1.16M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)(m)$19.67M$0.00-$18.62M
2024-09-30$36.70M(m)$40.27M$0.00-$2.27M
2023-09-30$26.87M(m)$38.20M$564.00K-$10.99M
2022-09-30(m)(m)$64.12M$0.00-$65.20M
2021-09-30(m)$18.83M$27.40M(m)-$28.43M
2020-09-30(m)$12.82M$20.58M(m)-$20.89M
2019-09-30(m)$12.19M$19.11M(m)-$18.03M
2018-09-30(m)$2.42M$4.39M(m)-$8.26M

Revenue and expense 10 month

Period endResearch and developmentOperating expensesNet income
2017-12-31$1.33M$1.71M-$2.26M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)(m)$23.63M$0.00-$22.40M
2024-12-31$41.09M(m)$49.36M$361.00K-$8.07M
2023-12-31$36.08M$37.04M$50.61M$580.00K-$13.34M
2022-12-31$15.76M$37.55M$77.83M$0.00-$62.43M
2021-12-31(m)$26.38M$37.79M$0.00-$39.05M
2020-12-31(m)$19.38M$29.55M$0.00-$29.81M
2019-12-31(m)$17.64M$26.73M(m)-$25.60M
2018-12-31(m)$4.94M$8.62M(m)-$13.25M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
GENELUX Corp (GNLX)United States$0.110B-3.83
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
ProMIS Neurosciences Inc. (PMN)$0.102B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49